Sumitomo Mitsui Trust Group
VERV

Sumitomo Mitsui Trust Group’s Verve Therapeutics VERV Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,115,466
Closed -$5.44M – 1107
2024
Q2 		$5.44M Sell
1,115,466
-1,476,732
-57% -$9.28M ﹤0.01% 745
2024
Q1 		$34.4M Buy
2,592,198
+194,594
+8% +$2.58M 0.02% 595
2023
Q4 		$33.4M Buy
2,397,604
+250,361
+12% +$3.1M 0.02% 595
2023
Q3 		$28.5M Sell
2,147,243
-38,614
-2% -$622K 0.02% 612
2023
Q2 		$41M Buy
2,185,857
+587,863
+37% +$9.79M 0.03% 528
2023
Q1 		$23M Buy
1,597,994
+369,547
+30% +$7.24M 0.02% 699
2022
Q4 		$23.8M Buy
1,228,447
+452,750
+58% +$12M 0.02% 681
2022
Q3 		$26.6M Buy
775,697
+660,465
+573% +$21.1M 0.02% 656
2022
Q2 		$1.76M Buy
+115,232
New +$1.78M ﹤0.01% 967
2022
Q1 		– Sell
-70,950
Closed -$2.62M – 1242
2021
Q4 		$2.62M Sell
70,950
-7,471
-10% -$314K ﹤0.01% 905
2021
Q3 		$3.69M Buy
+78,421
New +$4.61M ﹤0.01% 866

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group's VERV Position: Q3 2024 in Review

Sumitomo Mitsui Trust Group sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 1,115,466 shares — an estimated $5.44M sold.

Sumitomo Mitsui Trust Group first reported a position in VERV in Q3 2021 and held it in 11 quarters. The position peaked at $41M in Q2 2023. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Sumitomo Mitsui Trust Group reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 1,115,466 Verve Therapeutics shares in Q3 2024, an estimated $5.44M.
  • Sumitomo Mitsui Trust Group first reported a position in Verve Therapeutics in Q3 2021 and held it in 11 quarters.
  • Sumitomo Mitsui Trust Group's Verve Therapeutics position peaked at $41M in Q2 2023.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2024, filed 5 Nov 2024.